Jin Rong Jie·2025-12-18 11:42Core Insights - Fosun Pharma has entered into a strategic collaboration with Clavis Bio to develop innovative therapies based on cutting-edge targets nominated by Clavis Bio [1][2] - The collaboration will last for five years, with a focus on selecting and advancing up to four targets each year for preclinical development [1] - Clavis Bio will have exclusive licensing options for global development, production, and commercialization outside of mainland China and Hong Kong, while Fosun Pharma retains exclusive rights in these regions [1] Financial Aspects - If Clavis Bio exercises its option for a project, Fosun Pharma could receive up to $362.5 million in payments, including non-refundable option fees, milestone payments, and royalties based on net sales [2] - Fosun Pharma will also acquire a minority stake in a newly established project company by Aditum Bio at no cost, corresponding to the collaboration project [2] Strategic Goals - The collaboration aims to leverage Fosun Pharma's R&D strengths alongside Clavis Bio and Aditum Bio's expertise in clinical development and global operations [2] - The partnership is expected to enrich Fosun Pharma's high-value product pipeline and expand its innovative product offerings internationally [2] - Fosun Pharma's Chairman expressed optimism about the collaboration, emphasizing the goal of efficiently translating early potential targets into clinical value for global patients [2]